Untreated hiv infection leads to deterioration of immune system functioning

References

  1. Fauci AS, Lane HC: Harrison's Principles of Internal Medicine. 2005, 1: p1076-1139. Chapter 173. Human Immunodeficiency Virus Disease: AIDS and Related Disorders McGraw-Hill, Fauci AS, Lane HC, 16, Harrison's Principles of Internal Medicine Kasper Dennis L, Braunwald Eugene, Fauci Anthony S, Hauser Stephen L, Longo Dan L, Jameson J Larry, Isselbacher Kurt J,

    Google Scholar 

  2. Murray PR, Rosenthal KS, Pfaller MA: Medical Microbiology. 2005, 1: 963-Philadelphia, USA, Elsevier Mosby, 5th,

    Google Scholar 

  3. Miedema F: T cell dynamics and protective immunity in HIV infection: a brief history of ideas. Current Opinion in HIV & AIDS. 2006, 1 (1): 1-2.

    Article  Google Scholar 

  4. Pantaleo G, Fauci AS: IMMUNOPATHOGENESIS OF HIV INFECTION. Annual Review of Microbiology. 1996, 50 (1): 825-854. 10.1146/annurev.micro.50.1.825

    Article  CAS  PubMed  Google Scholar 

  5. Osmond DH: Figure 1. Generalized time course of HIV infection and disease. Edited by: HIV EDP. 1998, Modified from: Centers for Disease Control and Prevention. Report of the NIH Panel to Define Principles of Therapy of HIV Infection and Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. MMWR 1998;47(No. RR-5):Figure 1, page 34 . HIV InSite Knowledge Base Chapter,

    Google Scholar 

  6. Bartlett JG, Lane HC: Guidelines for the use of Antiretroviral Drugs in HIV-1-Infected Adults and Adolescents. Clinical Guidelines for the Treatment and Managment of HIV Infection. Edited by: Infection PCPTHIV. 2005, 1-118. USA , Department of Health and Human Services,

    Google Scholar 

  7. Stebbing J, Gazzard B, Douek DC: Mechanisms of disease - Where does HIV live?. New England Journal of Medicine. 2004, 350 (18): 1872-1880. 10.1056/NEJMra032395

    Article  CAS  PubMed  Google Scholar 

  8. Chinen J, Shearer WT: Molecular virology and immunology of HIV infection. Journal of Allergy and Clinical Immunology. 2002, 110 (2): 189-198. 10.1067/mai.2002.126226.

    Article  CAS  PubMed  Google Scholar 

  9. Phillips AN, Lundgren JD: The CD4 lymphocyte count and risk of clinical progression. Current Opinion in HIV & AIDS. 2006, 1 (1): 43-49.

    Article  Google Scholar 

  10. CASCADE collaboration: Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS. 2004, 18 (1): 51-58. 10.1097/00002030-200401020-00006

    Article  Google Scholar 

  11. Zhou J, Kumarasamy N: Predicting short-term disease progression among HIV-infected patients in Asia and the Pacific region: preliminary results from the TREAT Asia HIV Observational Database (TAHOD). HIV Medicine. 2005, 6 (3): 216-223. 10.1111/j.1468-1293.2005.00292.x

    Article  CAS  PubMed  Google Scholar 

  12. de Wolf F, Spijkerman I, Schellekens P, Langendam M, Kuiken C, Bakker M, Roos M, Coutinho R, Miedema F, Goudsmit J: AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS. 1997, 11 (15): 1799-1806. 10.1097/00002030-199715000-00003

    Article  CAS  PubMed  Google Scholar 

  13. Lepri AC, Katzenstein TL, Ullum H, Phillips AN, Skinhoj P, Gerstoft J, Pedersen B: The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection. AIDS. 1998, 12 (13): 1639-1643. 10.1097/00002030-199813000-00011

    Article  Google Scholar 

  14. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJP, O'Shaughnessy MV, Montaner JSG: Rates of Disease Progression by Baseline CD4 Cell Count and Viral Load After Initiating Triple-Drug Therapy. JAMA. 2001, 286 (20): 2568-2577. 10.1001/jama.286.20.2568

    Article  CAS  PubMed  Google Scholar 

  15. Goujard C, Bonarek M, Meyer L, Bonnet F, Chaix ML, Deveau C, Sinet M, Galimand J, Delfraissy JF, Venet A, Rouzioux C, Morlat P: CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clinical Infectious Diseases. 2006, 42 (5): 709-715. 10.1086/500213

    Article  CAS  PubMed  Google Scholar 

  16. Moore RD, Chaisson RE: Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS. 1999, 13 (14): 1933-1942. 10.1097/00002030-199910010-00017

    Article  CAS  PubMed  Google Scholar 

  17. Duncombe C, Kerr SJ, Ruxrungtham K, Dore GJ, Law MG, Emery S, Lange JA, Phanuphak P, Cooper DA: HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting. Aids. 2005, 19 (2): 169-178. 10.1097/00002030-200501280-00009

    Article  PubMed  Google Scholar 

  18. Grabar S, Moing VL, Goujard C, Leport C, Kazatchkine MD, Costagliola D, Weiss L: Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy. Ann Intern Med. 2000, 133 (6): 401-410.

    Article  CAS  PubMed  Google Scholar 

  19. van Leth F, Andrews S, Grinsztejn B, Wilkins E, Lazanas MK, Lange JMA, Montaner J: The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. Aids. 2005, 19 (5): 463-471. 10.1097/01.aids.0000162334.12815.5b

    Article  CAS  PubMed  Google Scholar 

  20. Battegay M, Nuesch R, Hirschel B, Kaufmann GR: Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infectious Diseases. 2006, 6 (5): 280-287. 10.1016/S1473-3099(06)70463-7

    Article  CAS  PubMed  Google Scholar 

  21. Ogg GS, Jin X, Bonhoeffer S, Dunbar PR, Nowak MA, Monard S, Segal JP, Cao Y, Rowland-Jones SL, Cerundolo V, Hurley A, Markowitz M, Ho DD, Nixon DF, McMichael AJ: Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 1998, 279 (5359): 2103-2106. 10.1126/science.279.5359.2103

    Article  CAS  PubMed  Google Scholar 

  22. Keoshkerian E, Ashton LJ, Smith DG, Ziegler JB, Kaldor JM, Cooper DA, Stewart GJ, Ffrench RA: Effector HIV-specific cytotoxic T-lymphocyte activity in long-term nonprogressors: Associations with viral replication and progression. Journal of Medical Virology. 2003, 71 (4): 483-491. 10.1002/jmv.10525

    Article  CAS  PubMed  Google Scholar 

  23. Oxenius A, Price DA, Hersberger M, Schlaepfer E, Weber R, Weber M, Kundig TM, Böni J, Joller H, Phillips RE, Flepp M, Opravil M, Speck RF: HIV-specific cellular immune response is inversely correlated with disease progression as defined by decline of CD4+ T cells in relation to HIV RNA load. The journal of infectious diseases. 2004, 189 (7): 1199-1208. 10.1086/382028

    Article  CAS  PubMed  Google Scholar 

  24. Chouquet C, Autran B, Gomard E, Bouley JM, Calvez V, Katlama C, Costagliola D, Rivière Y: Correlation between breadth of memory HIV-specific cytotoxic T cells, viral load and disease progression in HIV infection. AIDS. 2002, 16 (18): 2399-2407. 10.1097/00002030-200212060-00004

    Article  CAS  PubMed  Google Scholar 

  25. Macias J, Leal M, Delgado J, Pineda JA, Munoz J, Relimpio F, Rubio A, Rey C, Lissen E: Usefulness of route of transmission, absolute CD8+T-cell counts, and levels of serum tumor necrosis factor alpha as predictors of survival of HIV-1-infected patients with very low CD4+T-cell counts. European Journal of Clinical Microbiology & Infectious Diseases. 2001, 20 (4): 253-259.

    CAS  Google Scholar 

  26. Bonnet F, Thiebaut R, Chene G, Neau D, Pellegrin JL, Mercie P, Beylot J, Dabis F, Salamon R, Morlat P: Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002. Hiv Medicine. 2005, 6 (3): 198-205. 10.1111/j.1468-1293.2005.00290.x

    Article  CAS  PubMed  Google Scholar 

  27. Hazenberg MD, Otto SA, van Benthem BHB, Roos MTL, Coutinho RA, Lange JMA, Hamann D, Prins M, Miedema F: Persistent immune activation in HIV-1 infection is associated with progression to AIDS. Aids. 2003, 17 (13): 1881-1888. 10.1097/00002030-200309050-00006

    Article  PubMed  Google Scholar 

  28. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B, Teixeira-Johnson L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM, Deeks SG, Douek DC: Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nature Medicine. 2006, 12 (12): 1365-1371. 10.1038/nm1511

    Article  CAS  PubMed  Google Scholar 

  29. Kaushik S, Vajpayee M, Sreenivas V, Seth P: Correlation of T-lymphocyte subpopulations with immunological markers in HIV-1-infected Indian patients. Clinical Immunology. 2006, 119 (3): 330-338. 10.1016/j.clim.2005.12.014

    Article  CAS  PubMed  Google Scholar 

  30. Scriba TJ, Zhang HT, Brown HL, Oxenius A, Tamm N, Fidler S, Fox J, Weber JN, Klenerman P, Day CL, Lucas M, Phillips RE: HIV-1–specific CD4+ T lymphocyte turnover and activation increase upon viral rebound. Journal of Clinical Investigation. 2005, 115 (2): 443-450. 10.1172/JCI200523084

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Deeks SG, Walker BD: The immune response to AIDS virus infection: good, bad or both? . Journal of Clinical Investigation. 2004, 113 (6): 808-810. 10.1172/JCI200421318

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Benito DM, Lopez M, Lozano S, Ballesteros C, Martinez P, Gonzalez-Lahoz J, Soriano V: Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4(+) T cells under successful highly active antiretroviral therapy. Jaids-Journal of Acquired Immune Deficiency Syndromes. 2005, 38 (4): 373-381. 10.1097/01.qai.0000153105.42455.c2.

    Article  CAS  Google Scholar 

  33. Benito JM, Lopez M, Lozano S, Martinez P, Gonzaez-Lahoz J, Soriano V: CD38 expression on CD8(+) T lymphocytes as a marker of residual virus replication in chronically HIV-infected patients receiving antiretroviral therapy. Aids Research and Human Retroviruses. 2004, 20 (2): 227-233. 10.1089/088922204773004950.

    Article  CAS  PubMed  Google Scholar 

  34. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP, Shih R, Lewis J, Wiley DJ, Phair JP, Wolinsky SM, Detels R: Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. Journal of Infectious Diseases. 1999, 179 (4): 859-870. 10.1086/314660

    Article  CAS  PubMed  Google Scholar 

  35. Eggena MP, Barugahare B, Okello M, Mutyala S, Jones N, Ma YF, Kityo C, Mugyenyi P, Cao H: T cell activation in HIV-seropositive Ugandans: Differential associations with viral load, CD4(+) T cell depletion, and coinfection. Journal of Infectious Diseases. 2005, 191 (5): 694-701. 10.1086/427516

    Article  PubMed  Google Scholar 

  36. Deeks SG, Kitchen CMR, Liu L, Guo H, Gascon R, Narvaez AB, Hunt P, Martin JN, Kahn JO, Levy J, McGrath MS, Hecht FM: Immune activation set point during early FHV infection predicts subsequent CD4(+) T-cell changes independent of viral load. Blood. 2004, 104 (4): 942-947. 10.1182/blood-2003-09-3333

    Article  CAS  PubMed  Google Scholar 

  37. Wilson CM, Ellenberg JH, Douglas SD, Moscicki AB, Holland CA: CD8(+)CD38(+) T cells but not HIV type 1 RNA viral load predict CD4(+) T cell loss in a predominantly minority female HIV+ adolescent population. Aids Research and Human Retroviruses. 2004, 20 (3): 263-269. 10.1089/088922204322996482.

    Article  CAS  PubMed  Google Scholar 

  38. Connolly NC, Ridder SA, Rinaldo CR: Proinflammatory cytokines in HIV disease - a review and rationale for new therapeutic approaches. AIDS Reviews. 2005, 7: 168-180.

    PubMed  Google Scholar 

  39. Spear GT, Alves MEAF, Cohen MH, Bremer J, Landay AL: Relationship of HIV RNA and cytokines in saliva from HIV-infected individuals. FEMS Immunology and Medical Microbiology. 2005, 45: 129-136. 10.1016/j.femsim.2005.03.002.

    Article  CAS  PubMed  Google Scholar 

  40. Majumder B, Janket ML, Schafer EA, Schaubert K, Huang XL, Kan-Mitchell J, Rinaldo J, Ayyavoo V: Human Immunodeficiency Virus Type 1 Vpr Impairs Dendritic Cell Maturation and T-Cell Activation: Implications for Viral Immune Escape. JOURNAL OF VIROLOGY. 2005, 79 (13): 7990–8003-10.1128/JVI.79.13.7990-8003.2005.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  41. Fahey JL, Taylor JM, Detels R, Hofmann B, Melmed R, Nishanian P, Giorgi JV: The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med. 1990, 322 (3): 166-172.

    Article  CAS  PubMed  Google Scholar 

  42. Fahey JL, Taylor JMG, Manna B, Nishanian P, Aziz N, Giorgi JV, Detels R: Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. AIDS. 1998, 12 (13): 1581-1590. 10.1097/00002030-199813000-00004

    Article  CAS  PubMed  Google Scholar 

  43. Mildvan D, Spritzler J, Grossberg SE, Fahey JL, Johnston DM, Schock BR, Kagan J: Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection. Clinical Infectious Diseases. 2005, 40 (6): 853-858. 10.1086/427877

    Article  CAS  PubMed  Google Scholar 

  44. Shi MG, Taylor JMG, Fahey JL, Hoover DR, Munoz A, Kingsley LA: Early levels of CD4, neopterin, and beta(2)-microglobulin indicate future disease progression. Journal of Clinical Immunology. 1997, 17 (1): 43-52. 10.1023/A:1027336428736

    Article  CAS  PubMed  Google Scholar 

  45. Zangerle R, Steinhuber S, Sarcletti M, Dierich MP, Wachter H, Fuchs D, Most J: Serum HIV-1 RNA levels compared to soluble markers of immune activation to predict disease progression in HIV-1-infected individuals. International Archives of Allergy and Immunology. 1998, 116 (3): 228-239. 10.1159/000023949.

    Article  CAS  PubMed  Google Scholar 

  46. Stein DS, Lyles RH, Graham NMH, Tassoni CJ, Margolick JB, Phair JP, Rinaldo C, Detels R, Saah A, Bilello J: Predicting clinical progression or death in subjects with early-stage human immunodeficiency virus (HIV) infection: A comparative analysis of quantification of HIV RNA, soluble tumor necrosis factor type II receptors, neopterin, and beta(2)-microglobulin. Journal of Infectious Diseases. 1997, 176 (5): 1161-1167.

    Article  CAS  PubMed  Google Scholar 

  47. O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoit S, Rubin M, Simberkoff MS, Hamilton JD: Changes in Plasma HIV-1 RNA and CD4+ Lymphocyte Counts and the Risk of Progression to AIDS. N Engl J Med. 1996, 334 (7): 426-431. 10.1056/NEJM199602153340703

    Article  PubMed  Google Scholar 

  48. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saah AJ, Detels R, Phair JP, Rinaldo CR: Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection. Annals of Internal Medicine. 1997, 126 (12): 946-954.

    Article  CAS  PubMed  Google Scholar 

  49. Hammer S, WHO Guidelines Development Group: Antiretroviral therapy for HIV infection in Adults and Adolescents in resource-limited settings: Towards Universal Access Recommendations for a public health approach (2006 revision). Antiretroviral therapy for HIV infection in Adults and Adolescents in resource-limited settings: Towards Universal Access. Edited by: Hammer S. 2006, Geneva , WHO,

    Google Scholar 

  50. Gazzard B, BHIVA writing committee: British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). HIV medicine. 2005, 6 (Supplement 2): 1-61. 10.1111/j.1468-1293.2005.0311b.x.

    Article  PubMed  Google Scholar 

  51. Bhatia R, Narain JP: Guidelines for HIV DIAGNOSIS and Monitoring of ANTIRETROVIRAL THERAPY - South East Asia Regional Branch. World Health Organisation Publications. 2005

    Google Scholar 

  52. Lyles RH, Munoz A, Yamashita TE, Bazmi H, Detels R, Rinaldo CR, Margolick JB, Phair JP, Mellors JW: Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Journal of Infectious Diseases. 2000, 181 (3): 872-880. 10.1086/315339

    Article  CAS  PubMed  Google Scholar 

  53. Thiebaut R, Pellegrin I, Chene G, Viallard JF, Fleury H, Moreau JF, Pellegrin JL, Blanco P: Immunological markers after long-term treatment interruption in chronically HIV-1 infected patients with CD4 cell count above 400x10(6) cells/I. Aids. 2005, 19 (1): 53-61.

    Article  PubMed  Google Scholar 

  54. Arnaout RA, Lloyd AL, O'Brien TR, Goedert JJ, Leonard JM, Nowak MA: A simple relationship between viral load and survival time in HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America. 1999, 96 (20): 11549-11553. 10.1073/pnas.96.20.11549

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  55. Arduino JM, Fischl MA, Stanley K, Collier AC, Spiegelman D: Do HIV type 1 RNA levels provide additional prognostic value to CD4(+) T lymphocyte counts in patients with advanced HIV type 1 infection?. Aids Research and Human Retroviruses. 2001, 17 (12): 1099-1105. 10.1089/088922201316912709.

    Article  CAS  PubMed  Google Scholar 

  56. Ledergerber B: Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. The Lancet. 2004, 364 (9428): 51-62. 10.1016/S0140-6736(04)16589-6.

    Article  Google Scholar 

  57. Touloumi G, Hatzakis A, Rosenberg PS, O'Brien TR, Goedert JJ: Effects of age at seroconversion and baseline HIV RNA level on the loss of CD4+ cells among persons with hemophilia. Aids. 1998, 12 (13): 1691-1697. 10.1097/00002030-199813000-00018

    Article  CAS  PubMed  Google Scholar 

  58. Ho DD: Dynamics of HIV-1 replication in vivo. Journal of Clinical Investigation. 1997, 99 (11): 2565-2567.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  59. Hubert JB, Burgard M, Dussaix E, Tamalet C, Deveau C, Le Chenadec J, Chaix ML, Marchadier E, Vilde JL, Delfraissy JF, Meyer L, Rouzioux C: Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection. Aids. 2000, 14 (2): 123-131. 10.1097/00002030-200001280-00007

    Article  CAS  PubMed  Google Scholar 

  60. Relucio K, Holodniy M: HIV-1 RNA and viral load. Clinics in Laboratory Medicine. 2002, 22 (3): 593-+. 10.1016/S0272-2712(02)00008-2

    Article  PubMed  Google Scholar 

  61. Bajaria SH, Webb G, Cloyd M, Kirschner D: Dynamics of naive and memory CD4(+) T lymphocytes in HIV-1 disease progression. Journal of Acquired Immune Deficiency Syndromes. 2002, 30 (1): 41-58. 10.1097/00126334-200205010-00006

    Article  PubMed  Google Scholar 

  62. CASCADE collaboration, Babiker A, Darby S, De Angelis D, Kwart D, Porter K, Beral V, Darbyshire J, Day N, Gill N, Coutinho R, Prins M, van Benthem B, Coutinho R, Dabis F, Marimoutou C, Ruiz I, Tusell J, Altisent C, Evatt B, Jaffe H, Kirk O, Pedersen C, Rosenberg P, Goedert J, Biggar R, Melbye M, Brettie R, Downs A, Hamouda O, Touloumi G, Karafoulidou A, Katsarou O, Donfield S, Gomperts E, Hilgartner M, Hoots K, Schoenbaum E, Beral V, Zangerle R, Del Amo J, Pezzotti P, Rezza G, Hutchinson S, Day N, De Angelis D, Gore S, Kingsley L, Schrager L, Rosenberg P, Goedert J, Melnick S, Koblin B, Eskild A, Bruun J, Sannes M, Evans B, Lepri AC, Sabin C, Buchbinder S, Vittinghoff E, Moss A, Osmond D, Winkelstein W, Goldberg D, Boufassa F, Meyer L, Egger M, Francioli P, Rickenbach M, Cooper D, Tindall B, Sharkey T, Vizzard J, Kaldor J, Cunningham P, Vanhems P, Vizzard J, Kaldor J, Learmont J, Farewell V, Berglund O, Mosley J, Operskalski E, van den Berg M, Metzger D, Tobin D, Woody G, Rusnak J, Hendrix C, Garner R, Hawkes C, Renzullo P, Garland F, Darby S, Ewart D, Giangrande P, Lee C, Phillips A, Spooner R, Wilde J, Winter M, Babiker A, Darbyshire J, Evans B, Gill N, Johnson A, Phillips A, Porter K, Lorenzo JI, Schechter M: Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Lancet. 2000, 355 (9210): 1131-1137. 10.1016/S0140-6736(00)02061-4

    Article  Google Scholar 

  63. Desquilbet L, Goujard C, Rouzioux C, Sinet M, Deveau C, Chaix ML, Sereni D, Boufassa F, Delfraissy JF, Meyer L: Does transient HAART during primary HIV-1 infection lower the virological set-point?. Aids. 2004, 18 (18): 2361-2369.

    PubMed  Google Scholar 

  64. Olsen Jose b; Ledergerber, Bruno c; Katlama, Christine d; Friis-Moller, Nina a; Weber, Jonathan e; Horban, Andrzej f; Staszewski, Schlomo g; Lundgren, Jens D a; Phillips, Andrew N h; for the EuroSIDA Study Group * CHG, 2005. Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen. AIDS 19(3), 319–330.

    PubMed  Google Scholar 

  65. Raboud JM, Rae S, Hogg RS, Yip B, Sherlock CH, Harrigan PR, O'Shaughnessy MV, Montaner JS: Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation. The journal of infectious diseases. 1999, 180 (4): 1347-1350. 10.1086/314998

    Article  CAS  PubMed  Google Scholar 

  66. Raboud JM, Montaner JSG, Conway B, Rae S, Reiss P, Vella S, Cooper D, Lange O, Harris M, Wainberg MA, Robinson P, Myers M, Hall D: Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. Aids. 1998, 12 (13): 1619-1624. 10.1097/00002030-199813000-00008

    Article  CAS  PubMed  Google Scholar 

  67. Kempf DJ, Rode RA, Xu Y, Sun E, Heath-Chiozzi ME, Valdes J, Japour AJ, Danner S, Boucher C, Molla A, Leonard JM: The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS. 1998, 12 (5): F9-F14. 10.1097/00002030-199805000-00001

    Article  CAS  PubMed  Google Scholar 

  68. Tarwater PM, Gallant JE, Mellors JW, Gore ME, Phair JP, Detels R, Margolick JB, Munoz A: Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users. Aids. 2004, 18 (18): 2419-2423.

    PubMed  Google Scholar 

  69. Raffanti SP, Fusco JS, Sherrill BH, Hansen NI, Justice AC, D' Aquila R, Mangialardi WJ, Fusco GP: Effect of persistent moderate viremia on disease progression during HIV therapy. Jaids-Journal of Acquired Immune Deficiency Syndromes. 2004, 37 (1): 1147-1154. 10.1097/01.qai.0000136738.24090.d0.

    Article  Google Scholar 

  70. Murri R, Lepri AC, Cicconi P, Poggio A, Arlotti M, Tositti G, Santoro D, Soranzo ML, Rizzardini G, Colangeli V, Montroni M, Monforte AD: Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-Infected people treated with highly active Antiretroviral therapy - Evidence from the Italian Cohort of Antiretroviral-Naive Patients Study. Jaids-Journal of Acquired Immune Deficiency Syndromes. 2006, 41 (1): 23-30. 10.1097/01.qai.0000188337.76164.7a.

    Article  Google Scholar 

  71. Nettles RE, Kieffer TL, Kwon P, Monie D, Han YF, Parsons T, Cofrancesco J, Gallant JE, Quinn TC, Jackson B, Flexner C, Carson K, Ray S, Persaud D, Siliciano RF: Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. Jama-Journal of the American Medical Association. 2005, 293 (7): 817-829. 10.1001/jama.293.7.817.

    Article  CAS  Google Scholar 

  72. Havlir DV, Bassett R, Levitan D, Gilbert P, Tebas P, Collier AC, Hirsch MS, Ignacio C, Condra J, Gunthard HF, Richman DD, Wong JK: Prevalence and Predictive Value of Intermittent Viremia With Combination HIV Therapy. JAMA. 2001, 286 (2): 171-179. 10.1001/jama.286.2.171

    Article  CAS  PubMed  Google Scholar 

  73. Martinez V, Marcelin AG, Morini JP, Deleuze J, Krivine A, Gorin I, Yerly S, Perrin L, Peytavin G, Calvez V, Dupin N: HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS. 2005, 19 (10): 1065-1069. 10.1097/01.aids.0000174453.55627.de

    Article  PubMed  Google Scholar 

  74. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, Siliciano RF: Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4(+) T cells. Nature Medicine. 2003, 9 (6): 727-728. 10.1038/nm880

    Article  CAS  PubMed  Google Scholar 

  75. Haggerty CM, Pitt E, Siliciano RF: The latent reservoir for HIV-1 in resting CD4+ T cells and other viral reservoirs during chronic infection: insights from treatment and treatment-interruption trials. Current Opinion in HIV & AIDS. 2006, 1 (1): 62-68.

    Article  Google Scholar 

  76. Siliciano JD, Siliciano RF: The latent reservoir for HIV-1 in resting CD4R T cells: a barrier to cure. Current Opinion in HIV and AIDS. 2006, 1 (2): 121-128.

    PubMed  Google Scholar 

  77. Chun TW, Nickle DC, Justement JS, Large D, Semerjian A, Curlin ME, O'Shea MA, Hallahan CW, Daucher M, Ward DJ, Moir S, Mullins JI, Kovacs C, Fauci AS: HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. The journal of clinical investigation. 2005, 115 (11): 3250-3255. 10.1172/JCI26197

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  78. Anton PA, Mitsuyasu RT, Deeks SG, Scadden DT, Wagner B, Huang C, Macken C, Richman DD, Christopherson C, Borellini F, Lazar R, Hege KM: Multiple measures of HIV burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects. AIDS. 2003, 17 (1): 53-63. 10.1097/00002030-200301030-00008

    Article  CAS  PubMed  Google Scholar 

  79. Vitone F, Gibellini D, Schiavone P, Re MC: Quantitative DNA proviral detection in HIV-1 patients treated with antiretroviral therapy. Journal of Clinical Virology. 2005, 33 (3): 194-200.

    Article  CAS  PubMed  Google Scholar 

  80. Vray M, Meynard JL, Dalban C, Morand-Joubert L, Clavel F, Brun-Vezinet F, Peytavin G, Costagliola D, Girard PM, Group NT: Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088). Antiviral therapy. 2003, 8 (5): 427-434.

    CAS  PubMed  Google Scholar 

  81. Rodes B, Garcia F, Gutierrez C, Martinez-Picado J, Aguilera A, Saumoy M, Vallejo A, Domingo P, Dalmau D, Ribas MA, Blanco JL, Pedreira J, Perez-Elias MJ, Leal M, de Mendoza C, Soriano V: Impact of drug resistance genotypes on CD4+counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients. Journal of Medical Virology. 2005, 77 (1): 23-28. 10.1002/jmv.20395

    Article  CAS  PubMed  Google Scholar 

  82. Deeks SG: Determinants of virological response to antiretroviral therapy: Implications for long-term strategies. Clinical Infectious Diseases. 2000, 30: S177-S184. 10.1086/313855

    Article  CAS  PubMed  Google Scholar 

  83. Lucas GM: Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven. Journal of Antimicrobial Chemotherapy. 2005, 55 (4): 413-416. 10.1093/jac/dki042

    Article  CAS  PubMed  Google Scholar 

  84. Deeks SG: Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet. 2003, 362 (9400): 2002-2011. 10.1016/S0140-6736(03)15022-2

    Article  CAS  PubMed  Google Scholar 

  85. Vandamme AM, Sonnerborg A, Ait-Khaled M, Albert J, Asjo B, Bacheler L, Banhegyi D, Boucher C, Brun-Vezinet F, Camacho R, Clevenbergh P, Clumeck N, Dedes N, De Luca A, Doerr HW, Faudon JL, Gatti G, Gerstoft J, Hall WW, Hatzakis A, Hellmann N, Horban A, Lundgren JD, Kempf D, Miller M, Miller V, Myers TW, Nielsen C, Opravil M, Palmisano L, Perno CF, Phillips A, Pillay D, Pumarola T, Ruiz L, Salminen M, Schapiro J, Schmidt B, Schmit JC, Schuurman R, Shulse E, Soriano V, Staszewski S, Vella S, Youle M, Ziermann R, Perrin L: Updated European recommendations for the clinical use of HIV drug resistance testing. Antiviral Therapy. 2004, 9 (6): 829-848.

    CAS  PubMed  Google Scholar 

  86. Oette M, Kaiser R, Daumer M, Petch R, Fatkenhetter G, Carls H, Rockstroh JK, Schmaloer D, Stechel J, Feldt T, Pfister H, Haussinger D: Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. Jaids-Journal of Acquired Immune Deficiency Syndromes. 2006, 41 (5): 573-581. 10.1097/01.qai.0000214805.52723.c1.

    Article  Google Scholar 

  87. Shet A, Berry L, Mohri H, Mehandru S, Chung C, Kim A, Jean-Pierre P, Hogan C, Simon V, Boden D, Markowitz MT: Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1 - A decade of experience. Jaids-Journal of Acquired Immune Deficiency Syndromes. 2006, 41 (4): 439-446. 10.1097/01.qai.0000219290.49152.6a.

    Article  Google Scholar 

  88. Wensing AMJ, van de Vijver DA, Angarano G, Asjo B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kucherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, de Coul ELO, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stockl E, Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher CA: Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. Journal of Infectious Diseases. 2005, 192 (6): 958-966. 10.1086/432916

    Article  PubMed  Google Scholar 

  89. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P, Leechanachai P, Ariyadej S, Leenasirimakul P, Hammer S, Lallemant M: Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. New England Journal of Medicine. 2004, 351 (3): 229-240. 10.1056/NEJMoa041305

    Article  CAS  PubMed  Google Scholar 

  90. Melby T, DeSpirito M, DeMasi R, Heilek-Snyder G, Greenberg ML, Graham N: HIV-1 coreceptor use in triple-class treatment experienced patients: Baseline prevalence, correlates, and relationship to enfuvirtide response. Journal of Infectious Diseases. 2006, 194 (2): 238-246. 10.1086/504693

    Article  CAS  PubMed  Google Scholar 

  91. Daar ES, Lynn HS, Donfield SM, Lail A, O'Brien SJ, Huang W, Winkler CA: Stromal cell-derived factor-1 genotype, coreceptor tropism, and HIV type 1 disease progression. Journal of Infectious Diseases. 2005, 192 (9): 1597-1605. 10.1086/496893

    Article  PubMed  Google Scholar 

  92. Brumme ZL, Goodrich J, Mayer HB, Brumme CJ, Henrick BM, Wynhoven B, Asselin JJ, Cheung PK, Hogg RS, Montaner JSG, Harrigan PR: Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. Journal of Infectious Diseases. 2005, 192 (3): 466-474. 10.1086/431519

    Article  CAS  PubMed  Google Scholar 

  93. Kaslow RA, Dorak T, Tang J: Influence of host genetic variation on susceptibility to HIV type 1 infection. Journal of Infectious Diseases. 2005, 191: S68-S77. 10.1086/425269

    Article  PubMed  Google Scholar 

  94. Liu HL, Hwangbo Y, Holte S, Lee J, Wang CH, Kaupp N, Zhu HY, Celum C, Corey L, McElrath MJ, Zhu TF: Analysis of genetic polymorphisms in CCR5, CCR2, stromal cell-derived factor-1, RANTES, and dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in seronegative individuals repeatedly exposed to HIV-1. Journal of Infectious Diseases. 2004, 190 (6): 1055-1058. 10.1086/423209

    Article  CAS  PubMed  Google Scholar 

  95. Hogan CM, Hammer SM: Host determinants in HIV infection and disease - Part 2: Genetic factors and implications for antiretroviral therapeutics. Annals of Internal Medicine. 2001, 134 (10): 978-996.

    Article  CAS  PubMed  Google Scholar 

  96. Delobel P, Sandres-Saune K, Cazabat M, Pasquier C, Marchou B, Massip P, Izopet J: R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. Jaids-Journal of Acquired Immune Deficiency Syndromes. 2005, 38 (4): 382-392. 10.1097/01.qai.0000152835.17747.47.

    Article  Google Scholar 

  97. Skrabal K, Trouplin V, Labrosse B, Obry V, Damond F, Hance AJ, Clavel F, Mammano F: Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations. Aids. 2003, 17 (6): 809-814. 10.1097/00002030-200304110-00005

    Article  CAS  PubMed  Google Scholar 

  98. Brumme ZL, Dong WWY, Yip B, Wynhoven B, Hoffman NG, Swanstrom R, Jensen MA, Mullins JI, Hogg RS, Montaner JSG, Harrigan PR: Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. Aids. 2004, 18 (4): F1-F9. 10.1097/00002030-200403050-00001

    Article  CAS  PubMed  Google Scholar 

  99. Geretti AM: HIV-1 subtypes: epidemiology and significance for HIV management. Current opinion in infectious diseases. 2006, 19 (1): 1-7. 10.1097/01.qco.0000200293.45532.68

    Article  PubMed  Google Scholar 

  100. Rangsin R, Chiu J, Khamboonruang C, Sirisopana N, Eiumtrakul S, Brown AE, Robb M, Beyrer C, Ruangyuttikarn C, Markowitz LE, Nelson KE: The Natural History of HIV-1 Infection in Young Thai Men After Seroconversion. J Acquired Immunodeficiency Syndromes. 2004, 36 (1): 622-629. 10.1097/00126334-200405010-00011.

    Article  Google Scholar 

  101. Hu DJ, Vanichseni S, Mastro TD, Raktham S, Young NL, Mock PA, Subbarao S, Parekh BS, Srisuwanvilai L, Sutthent R, Wasi C, Heneine W, Choopanya K: Viral load differences in early infection with two HIV-1 subtypes. Aids. 2001, 15 (6): 683-691. 10.1097/00002030-200104130-00003

    Article  CAS  PubMed  Google Scholar 

  102. Kaleebu P, French N, Mahe C, Yirrell D, Watera C, Lyagoba F, Nakiyingi J, Rutebemberwa A, Morgan D, Weber J, Gilks C, Whitworth J: Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. Journal of Infectious Diseases. 2002, 185 (9): 1244-1250. 10.1086/340130

    Article  PubMed  Google Scholar 

  103. Alaeus A, Lidman K, Bjorkman A, Giesecke J, Albert J: Similar rate of disease progression among individuals infected with HIV-1 genetic subtypes A-D. AIDS. 1999, 13 (8): 901-907. 10.1097/00002030-199905280-00005

    Article  CAS  PubMed  Google Scholar 

  104. Gray L, Newell ML, Cortina-Borja M, Thorne C: Gender and race do not alter early-life determinants of clinical disease progression in HIV-1 vertically infected children - European Collaborative Study. Aids. 2004, 18 (3): 509-516. 10.1097/00002030-200402200-00018

    Article  Google Scholar 

  105. Stephenson JM, Griffioen A, Woronowski H, Phillips AN, Petruckevitch A, Keenlyside R, Johnson AM, Anderson J, Melville R, Jeffries DJ, Norman J, Barton S, Chard S, Sibley K, Mitchelmore M, Brettle R, Morris S, O'Dornen P, Russell J, Overington-Hickford L, O'Farrell N, Chappell J, Mulcahy RF, Moseley J, Lyons F, Welch J, Graham D, Fadojutimi M, Kitchen V, Wells C, Byrne G, Tobin J, Tucker L, Harindra V, Mercey DE, Allason-jones E, Campbell L, French R, Johnson MA, Reid A, Farmer D, Saint N, Olaitan A, Madge S, Forster G, Phillips M, Sampson K, Nayagam A, Edlin J, Bradbeer C, de Ruiter A, Hargreaves L, Doyle C: Survival and progression of HIV disease in women attending GUM/HIV clinics in Britain and Ireland. Sexually Transmitted Infections. 1999, 75 (4): 247-252.

    Article  Google Scholar 

  106. Anastos K, Schneider MF, Gange SJ, Minkoff H, Greenblatt RM, Feldman J, Levine A, Delapenha R, Cohen M: The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. Jaids-Journal of Acquired Immune Deficiency Syndromes. 2005, 39 (5): 537-544.

    CAS  Google Scholar 

  107. Anastos K, Gange SJ, Lau B, Weiser B, Detels R, Giorgi JV, Margolick JB, Cohen M, Phair J, Melnick S, Rinaldo CR, Kovacs A, Levine A, Landesman S, Young M, Munoz A, Greenblatt RM: Association of race and gender with HIV-1 RNA levels and immunologic progression. JAIDS. 2000, 24 (3): 218-226.

    CAS  PubMed  Google Scholar 

  108. Saul J, Erwin J, Sabin CA, Kulasegaram R, Peters BS: The relationships between ethnicity, sex, risk group, and virus load in human immunodeficiency virus type 1 antiretroviral-naive patients. Journal of Infectious Diseases. 2001, 183 (10): 1518-1521. 10.1086/320191

    Article  CAS  PubMed  Google Scholar 

  109. Brown AE, Malone JD, Zhou SY, Lane JR, Hawkes CA: Human immunodeficiency virus RNA levels in US adults: a comparison based upon race and ethnicity. The journal of infectious diseases. 1997, 176 (3): 794-797.

    Article  CAS  PubMed  Google Scholar 

  110. Morgan D, Mahe C, Mayanja B, Okongo JM, Lubega R, Whitworth JAG: HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries?. Aids. 2002, 16 (4): 597-603. 10.1097/00002030-200203080-00011

    Article  PubMed  Google Scholar 

  111. Julg B, Goebel FD: Susceptibility to HIV/AIDS: An individual characteristic we can measure?. Infection. 2005, 33 (3): 160-162. 10.1007/s15010-005-6305-4

    Article  CAS  PubMed  Google Scholar 

  112. Altfeld M, Addo MA, Rosenberg ES, Hecht FA, Lee PK, Vogel M, Yu XG, Draenert R, Johnston MN, Strick D, Allen TA, Feeney ME, Kahn JO, Sekaly RP, Levy JA, Rockstroh JK, Goulder PJR, Walker BD: Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. Aids. 2003, 17 (18): 2581-2591. 10.1097/00002030-200312050-00005

    Article  CAS  PubMed  Google Scholar 

  113. Boffito M, Winston A, Owen A: Host determinants of antiretroviral drug activity. Current opinion in infectious diseases. 2005, 18 (6): 543-549. 10.1097/01.qco.0000191507.48481.10

    Article  CAS  PubMed  Google Scholar 

  114. Phillips EJ: The pharmacogenetics of antiretroviral therapy. Current Opinion in HIV and AIDS 2006, 1:. 2006, 1 (3): 249-256.

    Article  Google Scholar 

  115. Haas DW: Pharmacogenomics and HIV therapeutics. Journal of Infectious Diseases. 2005, 191 (9): 1397-1400. 10.1086/429303

    Article  CAS  PubMed  Google Scholar 

  116. Nash D, Katyal M, Shah S: Trends in predictors of death due to HIV-related causes among persons living with AIDS in New York City: 1993-2001. Journal of Urban Health-Bulletin of the New York Academy of Medicine. 2005, 82 (4): 584-600. 10.1093/jurban/jti123

    PubMed Central  PubMed  Google Scholar 

  117. Darby SC, Ewart DW, Giangrande PLF, Spooner RJD, Rizza CR: Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. Lancet. 1996, 347 (9015): 1573-1579.

    Article  CAS  PubMed  Google Scholar 

  118. Operskalski EA, Stram DO, Lee H, Zhou Y, Donegan E, Busch MP, Stevens CE, Schiff ER, Dietrich SL, Mosley JW: Human-Immunodeficiency-Virus Type-1 Infection - Relationship of Risk Group and Age to Rate of Progression to Aids. Journal of Infectious Diseases. 1995, 172 (3): 648-655.

    Article  CAS  PubMed  Google Scholar 

  119. Geskus RB, Meyer L, Hubert JB, Schuitemaker H, Berkhout B, Rouzioux C, Theodorou ID, Delfraissy JF, Prins M, Coutinho RA: Causal pathways of the effects of age and the CCR5-Delta 32, CCR2-641, and SDF-1 3 ' A alleles on AIDS development. Jaids-Journal of Acquired Immune Deficiency Syndromes. 2005, 39 (3): 321-326. 10.1097/01.qai.0000142017.25897.06.

    Article  Google Scholar 

  120. CASCADE collaboration, Porter K, Babiker AG, Darbyshire JH, Pezzotti P, Bhaskaran K, Walker AS: Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet. 2003, 362 (9392): 1267-1274. 10.1016/S0140-6736(03)14570-9

    Article  Google Scholar 

  121. Touloumi G, Pantazis N, Babiker AG, Walker SA, Katsarou O, Karafoulidou A, Hatzakis A, Porter K: Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates. Aids. 2004, 18 (12): 1697-1705. 10.1097/01.aids.0000131395.14339.f5

    Article  CAS  PubMed  Google Scholar 

  122. Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC: Initial Plasma HIV-1 RNA Levels and Progression to AIDS in Women and Men. N Engl J Med. 2001, 344 (10): 720-725. 10.1056/NEJM200103083441003

    Article  CAS  PubMed  Google Scholar 

  123. Farzadegan H, Hoover DR, Astemborski J, Lyles CM, Margolick JB, Markham RB, Quinn TC, Vlahov D: Sex differences in HIV-1 viral load and progression to AIDS. Lancet. 1998, 352: 1510-1514. 10.1016/S0140-6736(98)02372-1

    Article  CAS  PubMed  Google Scholar 

  124. Donnelly CA, Bartley LM, Ghani AC, Le Fevre AM, Kwong GP, Cowling BJ, van Sighem AI, de Wolf F, Rode RA, Anderson RM: Gender difference in HIV-1 RNA viral loads. HIV medicine. 2005, 6 (3): 170-178. 10.1111/j.1468-1293.2005.00285.x

    Article  CAS  PubMed  Google Scholar 

  125. Sterling TR, Chaisson RE, Moore RD: HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS. 2001, 15 (17): 2251-2257. 10.1097/00002030-200111230-00006

    Article  CAS  PubMed  Google Scholar 

  126. Carre N, Deveau C, Belanger F, Boufassa F, Persoz A, Jadand C, Rouzioux C, Delfraissy JF, Bucquet D, Dellamonica P, Gallais H, Dormont J, Lefrere JJ, Cassuto JP, Dupont B, Vittecoq D, Herson S, Gastaut JA, Sereni D, Vilde JL, Brucker G, Katlama C, Sobel A, Duval J, Kazatchine M, Lebras P, Even P, Guillevin L: Effect of Age and Exposure Group on the Onset of Aids in Heterosexual and Homosexual Hiv-Infected Patients. Aids. 1994, 8 (6): 797-802.

    Article  CAS  PubMed  Google Scholar 

  127. Prins M, Veugelers PJ: Comparison of progression and non-progression in injecting drug users and homosexual men with documented dates of HIV-1 seroconversion. Aids. 1997, 11 (5): 621-631. 10.1097/00002030-199705000-00010

    Article  CAS  PubMed  Google Scholar 

  128. Rezza G: Determinants of progression to AIDS in HIV-infected individuals: An update from the Italian Seroconversion Study. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1998, 17: S13-S16.

    Article  PubMed  Google Scholar 

  129. Ironson G, O'Cleirigh C, Fletcher MA, Laurenceau JP, Balbin E, Klimas N, Schneiderman N, Solomon G: Psychosocial Factors Predict CD4 and Viral Load Change in Men and Women With Human Immunodeficiency Virus in the Era of Highly Active Antiretroviral Treatment. Psychosom Med. 2005, 67 (6): 1013-1021. 10.1097/01.psy.0000188569.58998.c8

    Article  PubMed Central  PubMed  Google Scholar 

  130. Leserman J, Petitto JM, Golden RN, Gaynes BN, Gu HB, Perkins DO, Silva SG, Folds JD, Evans DL: Impact of stressful life events, depression, social support, coping, and cortisol on progression to AIDS. American Journal of Psychiatry. 2000, 157 (8): 1221-1228. 10.1176/appi.ajp.157.8.1221

    Article  CAS  PubMed  Google Scholar 

  131. Leserman J, Petitto JM, Gu H, Gaynes BN, Barroso J, Golden RN, Perkins DO, Folds JD, Evans DL: Progression to AIDS, a clinical AIDS condition and mortality: psychosocial and physiological predictors. Psychological Medicine. 2002, 32 (6): 1059-1073. 10.1017/S0033291702005949

    Article  CAS  PubMed  Google Scholar 

  132. Ashton E, Vosvick M, Chesney M, Gore-Felton C, Koopman C, O'Shea K, Maldonado J, Bachmann MH, Israelski D, Flamm J, Spiegel D: Social support and maladaptive coping as predictors of the change in physical health symptoms among persons living with HIV/AIDS. Aids Patient Care and Stds. 2005, 19 (9): 587-598. 10.1089/apc.2005.19.587.

    Article  PubMed  Google Scholar 

  133. Parruti G, Manzoli L, Toro PM, D'Amico G, Rotolo S, Graziani V, Schioppa F, Consorte A, Alterio L, Toro GM, Boyle BA: Long-term adherence to first-line highly active antiretroviral therapy in a hospital-based cohort: Predictors and impact on virologic response and relapse. Aids Patient Care and Stds. 2006, 20 (1): 48-57. 10.1089/apc.2006.20.48.

    Article  CAS  PubMed  Google Scholar 

  134. Blatt SP, Hendrix CW, Butzin CA, Freeman TM, Ward WW, Hensley RE, Melcher GP, Donovan DJ, Boswell RN: Delayed-Type Hypersensitivity Skin Testing Predicts Progression to Aids in Hiv-Infected Patients. Annals of Internal Medicine. 1993, 119 (3): 177-184.

    Article  CAS  PubMed  Google Scholar 

  135. Anastos K, Shi Q, French AL, Levine A, Greenblatt RM, Williams C, DeHovitz J, Delapenha R, Hoover DR: Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-1-infected women receiving highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes: JAIDS. 2004, 35 (4): 383-392. 10.1097/00126334-200404010-00008.

    Article  PubMed  Google Scholar 

  136. Jones-Lopez EC, Okwera A, Mayanja-Kizza H, Ellner JJ, Mugerwa RD, Whalen CC: Delayed-type hypersensitivity skin test reactivity and survival in HIV-infected patients in Uganda: Should anergy be a criterion to start antiretroviral therapy in low-income countries?. American Journal of Tropical Medicine and Hygiene. 2006, 74 (1): 154-161.

    PubMed  Google Scholar 

  137. Lange CG, Lederman MM, Madero JS, Medvik K, Asaad R, Pacheko C, Carranza C, Valdez H: Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes. 2002, 30 (1): 33-40. 10.1097/00126334-200205010-00005

    Article  CAS  PubMed  Google Scholar 

  138. Lederman HM, Williams PL, Wu JW, Evans TG, Cohn SE, McCutchan JA, Koletar SL, Hafner R, Connick E, Valentine FT, McElrath MJ, Roberts NJ, Currier JS: Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4(+) cell depletion. Journal of Infectious Diseases. 2003, 188 (12): 1794-1803. 10.1086/379900

    Article  PubMed  Google Scholar 

  139. Lange CG, Lederman MM, Medvik K, Asaad R, Wild M, Kalayjian R, Valdez H: Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. Aids. 2003, 17 (14): 2015-2023. 10.1097/00002030-200309260-00002

    Article  PubMed  Google Scholar 

  140. WHO: SCALING UP ANTIRETROVIRAL THERAPY IN RESOURCE-LIMITED SETTINGS: TREATMENT GUIDELINES FOR A PUBLIC HEALTH APPROACH. Edited by: Hammer S. 2004, 1-68. Geneva , World Health Organisation 3 by 5 Initiative,

    Google Scholar 

  141. Costello C, Nelson KE, Suriyanon V, Sennun S, Tovanabutra S, Heilig CM, Shiboski S, Jamieson DJ, Robison V, Rungruenthanakit K, Duerr A: HIV-1 subtype E progression among northern Thai couples: traditional and non-traditional predictors of survival. Int J Epidemiol. 2005, 34 (3): 577-584. 10.1093/ije/dyi023

    Article  CAS  PubMed  Google Scholar 

  142. Lau B, Gange SJ, Phair JP, Riddler SA, Detels R, Margolick JB: Use of total lymphocyte count and hemoglobin concentration for monitoring progression of HIV infection. Jaids-Journal of Acquired Immune Deficiency Syndromes. 2005, 39 (5): 620-625.

    Google Scholar 

  143. Gange SJ, Lau B, Phair J, Riddler SA, Detels R, Margolick JB: Rapid declines in total lymphocyte count and hemoglobin in HIV infection begin at CD4 lymphocyte counts that justify antiretroviral therapy. Aids. 2003, 17 (1): 119-+. 10.1097/00002030-200301030-00016

    Article  PubMed  Google Scholar 

  144. Florence E, Dreezen C, Schrooten W, Van Esbroeck M, Kestens L, Fransen K, De Roo A, Colebunders R: The role of non-viral load surrogate markers in HIV-positive patient monitoring during antiviral treatment. International Journal of Std & Aids. 2004, 15 (8): 538-542. 10.1258/0956462041558159

    Article  CAS  Google Scholar 

  145. Badri M, Wood R: Usefulness of total lymphocyte count in monitoring highly active antiretroviral therapy in resource-limited settings. AIDS. 2003, 17 (4): 541-545. 10.1097/00002030-200303070-00009

    Article  PubMed  Google Scholar 

  146. Balakrishnan P, Solomon S, Kumarasamy N, Mayer KH: Low-cost monitoring of HIV infected individuals on highly active antiretroviral therapy (HAART) in developing countries. The Indian journal of medical research. 2005, 121 (4): 345-355.

    PubMed  Google Scholar 

  147. Maas JJ, Dukers N, Krol A, van Ameijden EJC, van Leeuwen R, Roos MTL, de Wolf F, Coutinho RA, Keet IPM: Body mass index course in asymptomatic HIV-infected homosexual men and the predictive value of a decrease of body mass index for progression to AIDS. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1998, 19 (3): 254-259.

    Article  CAS  PubMed  Google Scholar 

  148. Castetbon K, Anglaret X, Toure S, Chene G, Ouassa T, Attia A, N'Dri-Yoman T, Malvy D, Salamon R, Dabis F: Prognostic value of cross-sectional anthropometric indices on short-term risk of mortality in human immunodeficiency virus-infected adults in Abidjan, Cote d'Ivoire. American Journal of Epidemiology. 2001, 154 (1): 75-84. 10.1093/aje/154.1.75

    Article  CAS  PubMed  Google Scholar 

  149. Thiebaut R, Malvy D, Marimoutou C, Dabis F: Anthropometric indices as predictors of survival in AIDS adults. Aquitaine Cohort, France, 1985-1997. European Journal of Epidemiology. 2000, 16 (7): 633-639. 10.1023/A:1007696530440

    Article  CAS  PubMed  Google Scholar 

  150. Malvy D, Thiebaut R, Marimoutou C, Dabis F: Weight loss and body mass index as predictors of HIV disease progression to AIDS in adults. Aquitaine cohort, France, 1985-1997. Journal of the American College of Nutrition. 2001, 20 (6): 609-615.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  151. Paton NI, Sangeetha S, Earnest A, Bellamy R: The impact of malnutrition on survival and the CD4 count response in HIV-infected patients starting antiretroviral therapy. Hiv Medicine. 2006, 7 (5): 323-330. 10.1111/j.1468-1293.2006.00383.x

    Article  CAS  PubMed  Google Scholar 

  152. Mekonnen Y, Dukers N, Sanders E, Dorigo W, Wolday D, Schaap D, Geskus RB, Coutinho RA, Fontanet A: Simple markers for initiating antiretroviral therapy among HIV-infected Ethiopians. Aids. 2003, 17 (6): 815-819. 10.1097/00002030-200304110-00006

    Article  PubMed  Google Scholar 

  153. Mocroft A, Kirk O, Barton SE, Dietrich M, Proenca R, Colebunders R, Pradier C, D'Arminio Monforte A, Ledergerber B, Lundgren JD, group ESIDA: Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. AIDS. 1999, 13 (8): 943-950. 10.1097/00002030-199905280-00010

    Article  CAS  PubMed  Google Scholar 

Download references

What happens if HIV is left untreated?

Untreated, HIV typically turns into AIDS in about 8 to 10 years. When AIDS occurs, your immune system has been severely damaged. You'll be more likely to develop diseases that wouldn't usually cause illness in a person with a healthy immune system. These are called opportunistic infections or opportunistic cancers.

How does HIV affect immune system function?

HIV finds the white blood cells, called CD4 cells. HIV gets inside the CD4 cell and makes copies of itself. Then, HIV kills the CD4 cell and the new HIV copies find other CD4 cells to get inside and start the cycle again. HIV kills immune system cells that help the body fight infections and diseases.

How HIV infection leads to the immune deficiency?

What does HIV do to a person? HIV infects white blood cells of your immune system called CD4 cells, or helper T cells. It destroys CD4 cells, causing your white blood cell count to drop. This leaves you with an immune system that can't fight off infections, even those that wouldn't normally make you sick.

What are common causes of deterioration in HIV?

Deterioration of the immune system is caused by the decline in CD4+ T cells, which are key infection fighters. As soon as HIV enters the body, it begins to destroy these cells. Symptoms of opportunistic infections common with AIDS include: Coma.